File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

TitleIDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Authors
Issue Date2012
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2012, v. 119 n. 8, p. 1901-1903 How to Cite?
AbstractMutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role.
Persistent Identifierhttp://hdl.handle.net/10722/164835
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCairns, RAen_US
dc.contributor.authorIqbal, Jen_US
dc.contributor.authorLemonnier, Fen_US
dc.contributor.authorKucuk, Cen_US
dc.contributor.authorde Leval, Len_US
dc.contributor.authorJais, JPen_US
dc.contributor.authorParrens, Men_US
dc.contributor.authorMartin, Aen_US
dc.contributor.authorXerri, Len_US
dc.contributor.authorBrousset, Pen_US
dc.contributor.authorChan, LCen_US
dc.contributor.authorChan, WCen_US
dc.contributor.authorGaulard, Pen_US
dc.contributor.authorMak, TWen_US
dc.date.accessioned2012-09-20T08:10:33Z-
dc.date.available2012-09-20T08:10:33Z-
dc.date.issued2012en_US
dc.identifier.citationBlood, 2012, v. 119 n. 8, p. 1901-1903en_US
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/164835-
dc.description.abstractMutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role.-
dc.languageengen_US
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlooden_US
dc.rightsThis research was originally published in The Hematologist: ASH News and Reports. Author(s). Title. The Hematologist: ASH News and Reports. Year;Vol,Issue:pp-pp. © the American Society of Hematology.-
dc.subject.meshImmunoblastic Lymphadenopathy - enzymology - genetics - pathology-
dc.subject.meshIsocitrate Dehydrogenase - genetics-
dc.subject.meshLymphoma, T-Cell - enzymology - genetics - pathology-
dc.subject.meshLymphoma, T-Cell, Peripheral - enzymology - genetics - pathology-
dc.subject.meshMutation-
dc.titleIDH2 mutations are frequent in angioimmunoblastic T-cell lymphomaen_US
dc.typeArticleen_US
dc.identifier.emailChan, LC: chanlc@hkucc.hku.hken_US
dc.identifier.authorityChan, LC=rp00373en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1182/blood-2011-11-391748-
dc.identifier.pmid22215888-
dc.identifier.pmcidPMC3293643-
dc.identifier.scopuseid_2-s2.0-84857575341-
dc.identifier.hkuros206273en_US
dc.identifier.volume119en_US
dc.identifier.issue8en_US
dc.identifier.spage1901en_US
dc.identifier.epage1903en_US
dc.identifier.eissn1528-0020-
dc.identifier.isiWOS:000300713800019-
dc.publisher.placeUnited States-
dc.identifier.citeulike10196816-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats